glp 1 drugs australia GLP-1 analogues for medical weight loss The GLP-1 RA boom: Trends

Adequate fluid intake supports digestion and helps offset common side effects like constipation

For a brand-name drug to be approved, it must undergo extensive clinical trials to establish its safety and effectiveness

Previous research has looked at single substances such as alcohol and cannabis, but a 2026 observational study in the British Medical Journal looked at multiple substances and extended its reach into opioids

5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials

The initial evaluation of these molecules by the big pharma companies impressed some of the key GLP-1 veterans

Patients taking warfarin can usually continue their therapy without significant issues